Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Rheumatoid arthritis patients face unofficial postcode lottery for treatment:

11.10.2006
... survey reveals widespread contravention of government policy and NICE guidance

People suffering from the debilitating pain of rheumatoid arthritis (RA) face a postcode lottery over whether they can have access to a treatment that is known to improve their condition significantly.

New research published in the medical journal Rheumatology [1] today (11 October 2006) reveals that, despite the National Institute for Health and Clinical Excellence (NICE) approving anti-tumour necrosis factor alpha (TNF) therapy for RA in 2002, many primary care trusts are refusing to fund it adequately or are putting a cap on the numbers of patients that can be treated.

The picture is even worse for the use of anti-TNF therapy in other arthritic conditions such as psoriatic arthritis (PsA) and ankylosing spondylitis (AS) where NICE approval has only just been given or is being awaited.

As a result of these findings, rheumatologists are calling on the Government and primary care trusts to end the unofficial postcode lottery and ensure that every patient who meets the NICE criteria can receive anti-TNF therapy if their consultants consider it appropriate.

Dr Lesley Kay, a member of the British Society for Rheumatology Biologics Register (BSRBR) management committee and co-author of the research, said: “The BSRBR urges the Government and primary care trusts to put an end to this patently unfair situation, which is in direct contravention of government policy. The postcode lottery continues to operate, even though NICE aims to stop this happening. It's unfair on patients with these devastating, painful and unglamorous conditions to be forced to take a low priority and to be deprived of this very successful treatment.”

Randomised clinical trials have shown anti-TNF therapy is highly effective in the treatment of RA, juvenile idiopathic arthritis (JIA), PsA and AS. Not only can it arrest the progress of the disease, preventing deformity, but also patients report considerable improvements in symptoms such as joint pain, swelling, mobility and fatigue, and often say that the treatment has made them feel well in themselves for the first time in many years. [2]

However, when Dr Kay and Dr Ian Griffiths sent questionnaires on behalf of the BSRBR (which monitors the use of anti-TNF therapy) to 509 consultant rheumatologists in the UK, the responses on behalf of 252 consultants revealed a wide disparity in the provision of anti-TNF therapy across the country.

Dr Kay, a consultant rheumatologist at the Freeman Hospital and Newcastle University, Newcastle upon Tyne, UK, said: “Nearly half of the consultants (46%) indicated that they had some form of limitation in their prescribing of anti-TNF agents for RA according to NICE guidance. Of these, 70% said these limitations were mainly in the form of capped funding or capped numbers of patients; staffing or lack of other facilities was a problem for 21% and 9% respectively.

“The consultants said they faced problems such as a fixed number of patients that they were allowed to treat each month, fixed financial caps, bans on treating any more patients until the next financial year, and the fact that different primary care trusts had different financial limits. Waiting lists were also a means of controlling access to treatment, with some patients waiting as long as 156 weeks.”

For PsA, for which anti-TNF therapy received NICE approval in June 2006 after the survey had been completed, and AS, for which NICE is expected to issue guidance in 2007, the situation is even worse.

“Only 67% of consultants have any access to anti-TNF therapy for patients with PsA or AS, whilst their ability to prescribe according to the British Society for Rheumatologists’ guidance is limited to 25% for AS and 30% for PsA,” said Dr Kay.

“The fact that different funding organisations set different restrictions has led to variation of access for equally affected patients to effective treatment, depending on where they live. The survey was anonymous, so we cannot use our data to map the disparity in provision across the country.”

Dr Kay said this disparity in the provision of a treatment, which could change the lives of RA patients, inflicted great mental and physical pain on them, and she described the human suffering behind the figures.

“I often put it to patients that if you wanted to design torture for someone, you'd give them pain, uncertainty about what the next day and the future would be like (inflammatory arthritis varies enormously from day to day and from patient to patient so you can never plan anything and your friends and family start to think you are unreliable), deprive them of sleep (arthritis is usually at its worst during the night and first thing in the morning), and threaten their independence and their ability to earn money and look after their families. Then you'd add to it by saying that there are these drugs that could put it all right for many people, but you can't have them because somebody thinks they cost too much.”

She also urged NICE to issue guidance on anti-TNF therapy for AS as quickly as possible. “AS patients are in a difficult situation as there is really nothing else, apart from non-steroidal anti-inflammatories (NSAIDs), that helps, and these are known to have serious possible side-effects such as heart attacks and strokes, stomach ulcers, perforations and gastrointestinal bleeds. Conditions like AS don't get the publicity or sympathy that cancer does – look how fast Herceptin was processed – but it causes lifelong disability in patients who are typically young men.”

[1] “UK consultant rheumatologists’ access to biologic agents and views on the BSR Biologics Register” by L.J. Kay and I.D. Griffiths. Rheumatology Advance Access published on 11 October, 2006. doi:10.1093/rheumatology/kel333

[2] “Patients’ perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study” by N.J. Marshall, G. Wilson, K. Lapworth and L.J. Kay. Rheumatology 2004; 1034-1038.

[3] Rheumatoid arthritis affects three times as many women as men. Prevalence in the UK is approximately 0.5% in men and 1.8% in women, increasing after the age of 64 to 2% in men and 5% in women. There are many more people with less severe forms of RA that do not meet the diagnostic criteria for definite or classical disease.

[4] Anti-TNF therapies include etanercept and infliximab. NICE has approved both for the treatment of RA, and etanercept for JIA only. Anti-TNF therapy works by targeting circulating TNF alpha (a regulatory protein, released by the cells of the immune system, that controls generation of the immune response) and preventing it from activating the pathways in the immune system that lead to inflammation.

Lesley Kay | alfa
Further information:
http://ww.ncl.ac.uk
http://www.oxfordjournals.org/our_journals/brheum/press_releases/oct06.pdf

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

Im Focus: Optoelectronic Inline Measurement – Accurate to the Nanometer

Germany counts high-precision manufacturing processes among its advantages as a location. It’s not just the aerospace and automotive industries that require almost waste-free, high-precision manufacturing to provide an efficient way of testing the shape and orientation tolerances of products. Since current inline measurement technology not yet provides the required accuracy, the Fraunhofer Institute for Laser Technology ILT is collaborating with four renowned industry partners in the INSPIRE project to develop inline sensors with a new accuracy class. Funded by the German Federal Ministry of Education and Research (BMBF), the project is scheduled to run until the end of 2019.

New Manufacturing Technologies for New Products

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Hubble captures massive dead disk galaxy that challenges theories of galaxy evolution

22.06.2017 | Physics and Astronomy

New femto-camera with quadrillion fractions of a second resolution

22.06.2017 | Physics and Astronomy

Rice U. chemists create 3-D printed graphene foam

22.06.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>